Suven Life announces results of Phase 2A study in patients with moderate Alzheimer's disease

The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.

from India Infoline News Service https://ift.tt/2YdU6za